8-K: Alaunos Therapeutics Secures $2 Million Through Registered Direct Offering of Stock and Pre-Funded Warrants

Alaunos Therapeutics, Inc. has completed a registered direct offering, raising approximately $2 million by issuing common stock and pre-funded warrants for general corporate purposes.

Summary

• Alaunos Therapeutics, Inc. (TCRT) entered into a securities purchase agreement on June 20, 2025, for a registered direct offering.
• The offering involved the sale of 338,725 shares of common stock at a purchase price of $3.36 per share.
• Additionally, 271,674 pre-funded warrants to purchase common stock were sold at a purchase price of $3.359 per warrant, with a nominal exercise price of $0.001 per warrant share.
• The aggregate amount raised from this offering is approximately $2,048,225.02.
• The offering closed on June 24, 2025.
• Net proceeds from the offering are intended for general corporate purposes, including capital expenditures and working capital.
• The offering was conducted under the company's effective shelf registration statement on Form S-3 (File No. 333-266841), which became effective on September 7, 2022.
• Purchasers are subject to a beneficial ownership limitation of 4.99% (or 9.99% upon election) of the outstanding common stock after the issuance.

Sentiment

Score: 6

Explanation: The document reports a successful capital raise, which is generally positive for a company's liquidity and operational runway. However, it's a standard financing event without specific positive operational or financial performance updates, and it introduces potential dilution. The sentiment is moderately positive due to the successful funding.

Positives

• The offering provides Alaunos Therapeutics with approximately $2 million in net proceeds, enhancing its financial liquidity.
• Funds are designated for general corporate purposes, including capital expenditures and working capital, which can support ongoing operations and strategic initiatives.

Negatives

• The issuance of new shares and warrants could lead to dilution for existing shareholders, although the specific impact depends on the number of shares outstanding and market reaction.

Risks

• Reduction in the size or quantity of customer orders.
• Changes in demand for the company's products due to industry conditions.
• Changes in the world economy.
• Negative effects of seasonality on the business.
• Impact of any pandemic or similar events on the company's business and financial results.
• Fluctuations in the price of the company's common stock post-closing of the offering.
• Other risks and uncertainties detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Future Outlook

The company intends to use the net proceeds from the offering for general corporate purposes, which may include capital expenditures and working capital. Forward-looking statements are subject to various risks, including changes in customer orders, industry demand, global economy, seasonality, and potential impacts from pandemics.

Management Comments

• The filing was signed by Melinda Lackey, Title: Legal & Administration, on behalf of Alaunos Therapeutics, Inc.

Industry Context

This registered direct offering is a common method for biotechnology companies like Alaunos Therapeutics to raise capital, particularly for general corporate purposes, including funding research and development, clinical trials, or operational expenses, without the extensive marketing efforts of a traditional underwritten public offering. The use of pre-funded warrants can be attractive to investors seeking to manage beneficial ownership limitations.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new common stock and pre-funded warrants. However, the capital raise provides funding for company operations, which could benefit long-term shareholder value.
• Employees: The capital raise supports the company's ongoing operations and strategic initiatives, potentially ensuring job security and continued development.

Next Steps

• The company will use the net proceeds for general corporate purposes, including capital expenditures and working capital.
• The company will maintain the listing or quotation of its Common Stock on its Trading Market and apply to list all newly issued Shares and Warrant Shares on such market.
• The company will continue to file all required reports under the Exchange Act.

Key Dates

Keywords

Alaunos Therapeutics, TCRT, Registered Direct Offering, Common Stock, Pre-Funded Warrants, Capital Raise, SEC Filing, Form 8-K, Equity Financing, Biotechnology, Pharmaceuticals